<DOC>
	<DOCNO>NCT00046852</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy autologous peripheral stem cell transplantation immunotherapy may allow doctor give high dos chemotherapy drug kill cancer cell . Biological therapy use different way stimulate immune system stop cancer cell grow . PURPOSE : Randomized phase I/II trial study effectiveness combine chemotherapy peripheral stem cell transplantation follow immunotherapy treating patient multiple myeloma .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Followed By Immunotherapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility expand ex vivo autologous T cell infuse cell high-dose chemotherapy autologous peripheral blood stem cell rescue patient multiple myeloma . - Determine response rate progression-free survival patient receive anti-CD3/anti-CD28 expand autologous T cell either day 14 day 100 post-transplantation . - Compare response survival rate patient historical control . - Determine optimal schedule pneumococcal conjugate vaccine ( PCV ) induce anti-pneumococcal immune response post-transplantation patient . - Determine whether `` vaccine education '' antigen-presenting cell ( APCs ) stem cell graft result earlier and/or enhance immune response graft contain `` non-educated '' APCs patient . - Determine whether infusion T cell presensitized PCV expand ex vivo contribute anti-pneumococcal immune response patient . OUTLINE : This randomize , multicenter study . Patients receive cyclophosphamide IV 12 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 2 . Patients undergo leukapheresis collect mononuclear cell autologous T cell ( ATCs ) peripheral blood stem cell ( PBSCs ) . ATCs generate ex vivo expansion 8-14 day selection CD3+/CD28+ cell . Patients receive high-dose therapy comprise carmustine IV 2 hour day -2 melphalan IV 20 minute day -1 melphalan IV alone day -2 -1 ( day -1 ) . Autologous PBSCs reinfused day 0 . Patients also receive G-CSF SC begin day 1 continue blood count recover . Patients choose receive pneumococcal conjugate vaccine ( PCV ) randomize 1 4 treatment arm . - Arm I : Patients receive PCV intramuscularly prior transplantation ( 10-14 day lymphocyte collection ) post-transplantation ( 1 3 month ) plus costimulated ATCs IV 20-60 minute around day 12-14 post-transplantation . - Arm II : Patients receive PCV arm I receive ATCs around day 100 post-transplantation . - Arm III : Patients receive PCV post-transplantation ( 1 3 month ) plus ATCs arm I . - Arm IV : Patients receive PCV arm III ATCs arm II . Patients choose receive PCV receive ATCs day 12-14 PBSC transplantation . All patient offer standard pneumococcal polysaccharide vaccine 12 month . Patients follow twice weekly day 60 , weekly 4 month , monthly 6 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 16-46 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma require systemic treatment No obvious myelodysplastic change marrow PATIENT CHARACTERISTICS : Age 18 80 Performance status ECOG 02 ( ECOG 34 allow base solely bone pain ) Life expectancy Not specify Hematopoietic Not specify Hepatic No chronic active hepatitis No liver cirrhosis Renal Creatinine great 3.0 mg/dL No dialysis Cardiovascular LVEF least 45 % unless evidence untreated clinically significant functional impairment Pulmonary FEV_1 FVC least 50 % predict Total lung capacity least 50 % predict DLCO least 50 % predict Mild moderate pulmonary impairment ( low DLCO ) allow patient would receive study carmustine Patients unable complete pulmonary function test due bone pain fracture must highresolution CT scan chest arterial partial pressure oxygen great 70 Other No active infection require IV antibiotic HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Prior pulse dexamethasone ( 12 course ) allow Concurrent pulse dexamethasone allow mobilization therapy Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>infection</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>